The University of Chicago Header Logo

Connection

Richard Schilsky to Antineoplastic Agents

Back to Details
This is a "connection" page, showing publications Richard Schilsky has written about Antineoplastic Agents.
Richard Schilsky
Connection Strength
11.011
Antineoplastic Agents
  1. Regorafenib in Patients With Solid Tumors With BRAF Alterations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. JCO Precis Oncol. 2024 Apr; 8:e2300527.
    View in: PubMed
    Score: 0.431
  2. Sunitinib in Patients With Breast Cancer With FGFR1 or FGFR2 Amplifications or Mutations: Results From the Targeted Agent and Profiling Utilization Registry Study. JCO Precis Oncol. 2024 Feb; 8:e2300513.
    View in: PubMed
    Score: 0.426
  3. Nivolumab Plus Ipilimumab in Patients With Solid Tumors With ATM Mutations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. JCO Precis Oncol. 2023 Sep; 7:e2300279.
    View in: PubMed
    Score: 0.414
  4. Cobimetinib Plus Vemurafenib in Patients With Solid Tumors With BRAF Mutations: Results From the Targeted Agent and Profiling Utilization Registry Study. JCO Precis Oncol. 2023 Sep; 7:e2300385.
    View in: PubMed
    Score: 0.414
  5. Pertuzumab Plus Trastuzumab in Patients With Lung Cancer With ERBB2 Mutation or Amplification: Results From the Targeted Agent and Profiling Utilization Registry Study. JCO Precis Oncol. 2023 06; 7:e2300041.
    View in: PubMed
    Score: 0.407
  6. Olaparib in Patients With Metastatic Prostate Cancer With BRCA1/2 Mutation: Results From the TAPUR Study. JCO Precis Oncol. 2023 02; 7:e2200505.
    View in: PubMed
    Score: 0.398
  7. Cobimetinib Plus Vemurafenib in Patients With Colorectal Cancer With BRAF Mutations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. JCO Precis Oncol. 2022 Nov; 6:e2200191.
    View in: PubMed
    Score: 0.391
  8. Sunitinib in Patients with Metastatic Colorectal Cancer (mCRC) with FLT-3 Amplification: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. Target Oncol. 2020 12; 15(6):743-750.
    View in: PubMed
    Score: 0.342
  9. Reply to M. Hutton-Potts and A.M. Joshua. JCO Oncol Pract. 2020 05; 16(5):285-286.
    View in: PubMed
    Score: 0.327
  10. Determining If a Somatic Tumor Mutation Is Targetable and Options for Accessing Targeted Therapies. J Oncol Pract. 2019 11; 15(11):575-583.
    View in: PubMed
    Score: 0.312
  11. Accelerating anticancer drug development - opportunities and trade-offs. Nat Rev Clin Oncol. 2018 12; 15(12):777-786.
    View in: PubMed
    Score: 0.298
  12. Hans Christian Andersen and the Value of New Cancer Treatments. J Natl Cancer Inst. 2018 05 01; 110(5):441-442.
    View in: PubMed
    Score: 0.286
  13. American Society of Clinical Oncology Statement: Biosimilars in Oncology. J Clin Oncol. 2018 04 20; 36(12):1260-1265.
    View in: PubMed
    Score: 0.282
  14. Extended RAS Gene Mutation Testing in Metastatic Colorectal Carcinoma to Predict Response to Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Therapy: American Society of Clinical Oncology Provisional Clinical Opinion Update 2015. J Clin Oncol. 2016 Jan 10; 34(2):179-85.
    View in: PubMed
    Score: 0.239
  15. Gains Against Cancer, But Enter 'Financial Toxicity'. Manag Care. 2015 Oct; 24(10):46-7, 52-4.
    View in: PubMed
    Score: 0.239
  16. Modernizing Eligibility Criteria for Molecularly Driven Trials. J Clin Oncol. 2015 Sep 01; 33(25):2815-20.
    View in: PubMed
    Score: 0.236
  17. Improving evidence developed from population-level experience with targeted agents. Clin Pharmacol Ther. 2015 May; 97(5):478-87.
    View in: PubMed
    Score: 0.231
  18. Circadian variation in plasma 5-fluorouracil concentrations during a 24 hour constant-rate infusion. BMC Cancer. 2015 Feb 18; 15:69.
    View in: PubMed
    Score: 0.229
  19. Moving from evaluation to value in cancer care. Clin Cancer Res. 2015 Mar 01; 21(5):947-9.
    View in: PubMed
    Score: 0.224
  20. Optimizing dosing of oncology drugs. Clin Pharmacol Ther. 2014 Nov; 96(5):572-9.
    View in: PubMed
    Score: 0.221
  21. Implementing personalized cancer care. Nat Rev Clin Oncol. 2014 07; 11(7):432-8.
    View in: PubMed
    Score: 0.216
  22. Precision cancer medicine: the future is now, only better. Am Soc Clin Oncol Educ Book. 2014; 61-9.
    View in: PubMed
    Score: 0.212
  23. Reevaluating the accelerated approval process for oncology drugs. Clin Cancer Res. 2013 Jun 01; 19(11):2804-9.
    View in: PubMed
    Score: 0.201
  24. Role of randomized phase III trials in an era of effective targeted therapies. Nat Rev Clin Oncol. 2011 Dec 06; 9(4):208-14.
    View in: PubMed
    Score: 0.184
  25. GI cancers in 2010: New standards and a predictive biomarker for adjuvant therapy. Nat Rev Clin Oncol. 2011 Feb; 8(2):70-2.
    View in: PubMed
    Score: 0.173
  26. Optimizing collection of adverse event data in cancer clinical trials supporting supplemental indications. J Clin Oncol. 2010 Dec 01; 28(34):5046-53.
    View in: PubMed
    Score: 0.169
  27. Commentary: tackling the challenges of developing targeted therapies for cancer. Oncologist. 2010; 15(5):484-7.
    View in: PubMed
    Score: 0.161
  28. Data submission standards and evidence requirements. Oncologist. 2010; 15(5):488-91.
    View in: PubMed
    Score: 0.161
  29. Personalizing cancer care: American Society of Clinical Oncology presidential address 2009. J Clin Oncol. 2009 Aug 10; 27(23):3725-30.
    View in: PubMed
    Score: 0.155
  30. The Translational Research Working Group developmental pathway for anticancer agents (drugs or biologics). Clin Cancer Res. 2008 Sep 15; 14(18):5685-91.
    View in: PubMed
    Score: 0.147
  31. How not to treat cancer. Lancet Oncol. 2008 Jun; 9(6):504-5.
    View in: PubMed
    Score: 0.144
  32. Target practice: oncology drug development in the era of genomic medicine. Clin Trials. 2007; 4(2):163-6; discussion 173-7.
    View in: PubMed
    Score: 0.130
  33. The cancer and leukemia group B pharmacology and experimental therapeutics committee: a historical perspective. Clin Cancer Res. 2006 Jun 01; 12(11 Pt 2):3612s-6s.
    View in: PubMed
    Score: 0.125
  34. Are targeted therapies really targeted? Clin Adv Hematol Oncol. 2003 Dec; 1(12):722-3.
    View in: PubMed
    Score: 0.105
  35. Hurry up and wait: is accelerated approval of new cancer drugs in the best interests of cancer patients? J Clin Oncol. 2003 Oct 15; 21(20):3718-20.
    View in: PubMed
    Score: 0.104
  36. Pembrolizumab in Patients With Tumors With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry Study. J Clin Oncol. 2023 Nov 20; 41(33):5140-5150.
    View in: PubMed
    Score: 0.103
  37. End points in cancer clinical trials and the drug approval process. Clin Cancer Res. 2002 Apr; 8(4):935-8.
    View in: PubMed
    Score: 0.094
  38. Antineoplastic drugs administered during pregnancy. Semin Oncol. 2000 Dec; 27(6):618-22.
    View in: PubMed
    Score: 0.086
  39. Pharmacology and clinical status of capecitabine. Oncology (Williston Park). 2000 Sep; 14(9):1297-306; discussion 1309-11.
    View in: PubMed
    Score: 0.084
  40. The Drug Rediscovery protocol facilitates the expanded use of existing anticancer drugs. Nature. 2019 10; 574(7776):127-131.
    View in: PubMed
    Score: 0.079
  41. Comparative Assessment of Clinical Benefit Using the ESMO-Magnitude of Clinical Benefit Scale Version 1.1 and the ASCO Value Framework Net Health Benefit Score. J Clin Oncol. 2019 02 01; 37(4):336-349.
    View in: PubMed
    Score: 0.075
  42. Streamlining Adverse Events Reporting in Oncology: An American Society of Clinical Oncology Research Statement. J Clin Oncol. 2018 02 20; 36(6):617-623.
    View in: PubMed
    Score: 0.070
  43. Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial. JAMA. 2017 06 20; 317(23):2392-2401.
    View in: PubMed
    Score: 0.067
  44. Association of Biomarker-Based Treatment Strategies With Response Rates and Progression-Free Survival in Refractory Malignant Neoplasms: A Meta-analysis. JAMA Oncol. 2016 Nov 01; 2(11):1452-1459.
    View in: PubMed
    Score: 0.064
  45. Response. J Natl Cancer Inst. 2016 Mar; 108(3):djw001.
    View in: PubMed
    Score: 0.061
  46. Extended RAS Gene Mutation Testing in Metastatic Colorectal Carcinoma to Predict Response to Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Therapy: American Society of Clinical Oncology Provisional Clinical Opinion Update 2015 Summary. J Oncol Pract. 2016 Feb; 12(2):180-1.
    View in: PubMed
    Score: 0.060
  47. Impact of a Biomarker-Based Strategy on Oncology Drug Development: A Meta-analysis of Clinical Trials Leading to FDA Approval. J Natl Cancer Inst. 2015 Nov; 107(11).
    View in: PubMed
    Score: 0.060
  48. Impact of Precision Medicine in Diverse Cancers: A Meta-Analysis of Phase II Clinical Trials. J Clin Oncol. 2015 Nov 10; 33(32):3817-25.
    View in: PubMed
    Score: 0.059
  49. First-in-human, phase I study of elisidepsin (PM02734) administered as a 30-min or as a 3-hour intravenous infusion every three weeks in patients with advanced solid tumors. Invest New Drugs. 2015 Aug; 33(4):901-10.
    View in: PubMed
    Score: 0.058
  50. Challenges in initiating and conducting personalized cancer therapy trials: perspectives from WINTHER, a Worldwide Innovative Network (WIN) Consortium trial. Ann Oncol. 2015 Aug; 26(8):1791-8.
    View in: PubMed
    Score: 0.058
  51. Population pharmacodynamic study of amonafide: a Cancer and Leukemia Group B study. J Clin Oncol. 1995 Mar; 13(3):741-7.
    View in: PubMed
    Score: 0.057
  52. Clinical cancer advances 2015: Annual report on progress against cancer from the American Society of Clinical Oncology. J Clin Oncol. 2015 Mar 01; 33(7):786-809.
    View in: PubMed
    Score: 0.057
  53. Evaluation of food effect on pharmacokinetics of vismodegib in advanced solid tumor patients. Clin Cancer Res. 2013 Jun 01; 19(11):3059-67.
    View in: PubMed
    Score: 0.050
  54. Phase I clinical and pharmacology study of 502U83 given as a 24-h continuous intravenous infusion. Cancer Chemother Pharmacol. 1993; 31(4):283-8.
    View in: PubMed
    Score: 0.049
  55. Antifolates: the next generation. Semin Oncol. 1992 Dec; 19(6):707-19.
    View in: PubMed
    Score: 0.049
  56. Prospects for fertility after cancer chemotherapy. Semin Oncol. 1992 Oct; 19(5):597-604.
    View in: PubMed
    Score: 0.049
  57. Zoledronic acid preserves bone mineral density in premenopausal women who develop ovarian failure due to adjuvant chemotherapy: final results from CALGB trial 79809. Eur J Cancer. 2011 Mar; 47(5):683-9.
    View in: PubMed
    Score: 0.043
  58. An accelerated pathway for targeted cancer therapies. Nat Rev Drug Discov. 2011 02; 10(2):79-80.
    View in: PubMed
    Score: 0.043
  59. A Cancer and Leukemia Group B phase II study of sunitinib malate in patients with previously treated metastatic pancreatic adenocarcinoma (CALGB 80603). Oncologist. 2010; 15(12):1310-9.
    View in: PubMed
    Score: 0.043
  60. Cancer pharmacogenomics and pharmacoepidemiology: setting a research agenda to accelerate translation. J Natl Cancer Inst. 2010 Nov 17; 102(22):1698-705.
    View in: PubMed
    Score: 0.042
  61. Personalized medicine in oncology: the future is now. Nat Rev Drug Discov. 2010 05; 9(5):363-6.
    View in: PubMed
    Score: 0.041
  62. Ovarian function following radiation and chemotherapy for cancer. Semin Oncol. 1989 Oct; 16(5):425-36.
    View in: PubMed
    Score: 0.039
  63. Male fertility following cancer chemotherapy. J Clin Oncol. 1989 Mar; 7(3):295-7.
    View in: PubMed
    Score: 0.038
  64. Effects of cancer treatment on the reproductive system. Crit Rev Oncol Hematol. 1988; 8(2):153-71.
    View in: PubMed
    Score: 0.035
  65. Diagnosis, management, and evaluation of chemotherapy-induced peripheral neuropathy. Semin Oncol. 2006 Feb; 33(1):15-49.
    View in: PubMed
    Score: 0.031
  66. 3rd EORTC-NCI International Meeting on Cancer Molecular Markers: From Discovery to Clinical Practice. Expert Rev Mol Diagn. 2004 Jul; 4(4):431-3.
    View in: PubMed
    Score: 0.027
  67. A phase I study of cantuzumab mertansine administered as a single intravenous infusion once weekly in patients with advanced solid tumors. Clin Cancer Res. 2004 Jul 01; 10(13):4363-8.
    View in: PubMed
    Score: 0.027
  68. Phase I study of an oral formulation of ZD9331 administered daily for 28 days. J Clin Oncol. 2003 May 01; 21(9):1859-65.
    View in: PubMed
    Score: 0.025
  69. Highlights from: 27th congress of the European Society for Medical Oncology. Nice, France. October 18-22, 2002. Clin Colorectal Cancer. 2002 Nov; 2(3):140-5.
    View in: PubMed
    Score: 0.024
  70. Phase I trial and pharmacokinetics of aziridinylbenzoquinone (NSC 182986) in humans. Cancer Res. 1982 Apr; 42(4):1582-6.
    View in: PubMed
    Score: 0.023
  71. Renal and metabolic toxicities of cancer chemotherapy. Semin Oncol. 1982 Mar; 9(1):75-83.
    View in: PubMed
    Score: 0.023
  72. Estimation of the effect of food on the disposition of oral 5-fluorouracil in combination with eniluracil. Cancer Chemother Pharmacol. 2002 May; 49(5):398-402.
    View in: PubMed
    Score: 0.023
  73. Silence is golden: gene hypermethylation and survival in large-cell lymphoma. J Natl Cancer Inst. 2002 Jan 02; 94(1):6-7.
    View in: PubMed
    Score: 0.023
  74. Long-term follow up of ovarian function in women treated with MOPP chemotherapy for Hodgkin's disease. Am J Med. 1981 Oct; 71(4):552-6.
    View in: PubMed
    Score: 0.023
  75. Phase I clinical and pharmacogenetic study of weekly TAS-103 in patients with advanced cancer. J Clin Oncol. 2001 Apr 01; 19(7):2084-90.
    View in: PubMed
    Score: 0.022
  76. Phase I study of ZD9331 on short daily intravenous bolus infusion for 5 days every 3 weeks with fixed dosing recommendations. J Clin Oncol. 2001 Mar 01; 19(5):1476-84.
    View in: PubMed
    Score: 0.022
  77. Gonadal dysfunction in patients receiving chemotherapy for cancer. Ann Intern Med. 1980 Jul; 93(1):109-14.
    View in: PubMed
    Score: 0.021
  78. O6-benzylguanine in humans: metabolic, pharmacokinetic, and pharmacodynamic findings. J Clin Oncol. 1998 May; 16(5):1803-10.
    View in: PubMed
    Score: 0.018
  79. Phase II and pharmacodynamic studies of pyrazine diazohydroxide (NSC 361456) in patients with advanced renal and colorectal cancer. Clin Cancer Res. 1998 Apr; 4(4):929-34.
    View in: PubMed
    Score: 0.018
  80. Phase I clinical and pharmacokinetic study of oral 9-aminocamptothecin (NSC-603071). Cancer Chemother Pharmacol. 1998; 42(1):84-7.
    View in: PubMed
    Score: 0.017
  81. Modulation of vinblastine resistance in metastatic renal cell carcinoma with cyclosporine A or tamoxifen: a cancer and leukemia group B study. Clin Cancer Res. 1997 Nov; 3(11):1977-84.
    View in: PubMed
    Score: 0.017
  82. Etoposide combined with interferon alfa-2b: novel exploitation of established etoposide pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther. 1996 Mar; 59(3):349-59.
    View in: PubMed
    Score: 0.015
  83. Individualized dosing of amonafide based on a pharmacodynamic model incorporating acetylator phenotype and gender. Pharmacogenetics. 1996 Feb; 6(1):93-101.
    View in: PubMed
    Score: 0.015
  84. Phase I study of adozelesin administered by 24-hour continuous intravenous infusion. J Natl Cancer Inst. 1994 Mar 02; 86(5):368-72.
    View in: PubMed
    Score: 0.013
  85. Phase II study of amonafide in gastric adenocarcinoma. An Illinois Cancer Center trial. Invest New Drugs. 1994; 12(3):267-70.
    View in: PubMed
    Score: 0.013
  86. Phase I and pharmacokinetic study of a new antineoplastic agent: pyrazine diazohydroxide (NSC 361456). Cancer Res. 1994 Jan 01; 54(1):114-9.
    View in: PubMed
    Score: 0.013
  87. Statistical and ethical issues in the design and conduct of phase I and II clinical trials of new anticancer agents. J Natl Cancer Inst. 1993 Oct 20; 85(20):1637-43.
    View in: PubMed
    Score: 0.013
  88. Phase I study of amonafide dosing based on acetylator phenotype. Cancer Res. 1993 May 15; 53(10 Suppl):2304-8.
    View in: PubMed
    Score: 0.013
  89. Biologic determinants of tumor recurrence in stage II colon cancer: validation study of the 12-gene recurrence score in cancer and leukemia group B (CALGB) 9581. J Clin Oncol. 2013 May 10; 31(14):1775-81.
    View in: PubMed
    Score: 0.013
  90. Paradoxical relationship between acetylator phenotype and amonafide toxicity. Clin Pharmacol Ther. 1991 Nov; 50(5 Pt 1):573-9.
    View in: PubMed
    Score: 0.011
  91. Pharmacodynamics in cancer therapy. J Clin Oncol. 1990 Oct; 8(10):1739-53.
    View in: PubMed
    Score: 0.011
  92. Refocusing the war on cancer: the critical role of personalized treatment. Sci Transl Med. 2010 Apr 21; 2(28):28cm13.
    View in: PubMed
    Score: 0.010
  93. Cyclooxygenase-2 and cancer treatment: understanding the risk should be worth the reward. Clin Cancer Res. 2010 Mar 01; 16(5):1384-90.
    View in: PubMed
    Score: 0.010
  94. The role of high-dose therapy and autologous bone marrow reinfusion in the treatment of malignant lymphomas. Cancer Invest. 1988; 6(4):427-37.
    View in: PubMed
    Score: 0.009
  95. Biomarkers, surrogate end points, and the acceleration of drug development for cancer prevention and treatment: an update prologue. Clin Cancer Res. 2004 Jun 01; 10(11):3881-4.
    View in: PubMed
    Score: 0.007
  96. Chemotherapy for testicular cancer: current status of the National Cancer Institute Combined Modality Trial. Cancer Treat Rep. 1979 Sep-Oct; 63(9-10):1687-92.
    View in: PubMed
    Score: 0.005
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.